Payment overview · 2025
General Payments
$1,507.71
76 reported records · 18 companies
Healthcare provider profile · identity verified
Patricia Weaver
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BENNETTSVILLE, SC · NPI 1356456628
Verified facts
What the public records show
CMS Open Payments records show Patricia Weaver received $1,507.71 in general payments during 2025 across 76 reported records.
ABBVIE INC. accounted for 23.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 505 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $348.40 | 23.1% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $315.60 | 20.9% | 11 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $139.64 | 9.3% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $93.29 | 6.2% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $92.38 | 6.1% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $91.45 | 6.1% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $75.78 | 5.0% | 5 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $61.01 | 4.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.54 | 2.8% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $40.06 | 2.7% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $37.88 | 2.5% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $36.21 | 2.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.97 | 2.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $25.36 | 1.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.06 | 1.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.48 | 1.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.24 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.36 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,507.71 | 76 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $292.93 | 14 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $242.41 | 8 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $139.64 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $131.60 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $93.29 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $92.38 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $91.45 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $73.19 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $61.92 | 4 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $61.01 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $55.47 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.54 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.54 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $40.06 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $37.88 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $36.21 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $35.97 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.14 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $25.36 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.06 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 65 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 62 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 505 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 44 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
62 | 29 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
84 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
62 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
83 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
505 | 95 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
44 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 519 | 159 |
| Ozempic | Semaglutide | 505 | 95 |
| Atorvastatin Calcium | Atorvastatin Calcium | 485 | 146 |
| Metformin Hcl | Metformin Hcl | 243 | 79 |
| Lisinopril | Lisinopril | 230 | 66 |
| Gabapentin | Gabapentin | 219 | 62 |
| Pravastatin Sodium | Pravastatin Sodium | 208 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 192 | 64 |
| Furosemide | Furosemide | 187 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 181 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 180 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 151 | 44 |
| Omeprazole | Omeprazole | 141 | 52 |
| Tramadol Hcl | Tramadol Hcl | 140 | 35 |
| Ibandronate Sodium | Ibandronate Sodium | 128 | 45 |
| Losartan Potassium | Losartan Potassium | 117 | 35 |
| Fluconazole | Fluconazole | 114 | 65 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 112 | 34 |
| Potassium Chloride | Potassium Chloride | 111 | 43 |
| Simvastatin | Simvastatin | 111 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 31 |
| Chlorthalidone | Chlorthalidone | 107 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 47 |
| Nifedipine Er | Nifedipine | 98 | 32 |
| Carvedilol | Carvedilol | 97 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 30 |
| Alprazolam | Alprazolam | 91 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 89 | 27 |
| Allopurinol | Allopurinol | 87 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 27 |
| Meloxicam | Meloxicam | 85 | 28 |
| Jardiance | Empagliflozin | 84 | 33 |
| Trulicity | Dulaglutide | 83 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 75 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 21 |
| Montelukast Sodium | Montelukast Sodium | 68 | 19 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 68 | 14 |
| Farxiga | Dapagliflozin Propanediol | 65 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 22 |
| Linzess | Linaclotide | 62 | 29 |
| Mounjaro | Tirzepatide | 62 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 60 | 23 |
| Pregabalin | Pregabalin | 55 | suppressed |
| Ezetimibe | Ezetimibe | 54 | 17 |
| Novolog Flexpen | Insulin Aspart | 54 | 20 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 53 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 17 |
| Sertraline Hcl | Sertraline Hcl | 52 | 16 |
| Lorazepam | Lorazepam | 51 | suppressed |
| Famotidine | Famotidine | 50 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 40 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 24 |
| Rybelsus | Semaglutide | 44 | 15 |
| Ibuprofen | Ibuprofen | 43 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 14 |
| Trueplus Pen Needle | Pen Needle, Diabetic | 40 | 16 |
| Atenolol | Atenolol | 38 | 11 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 20 |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 13 |
| Sucralfate | Sucralfate | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 16 |
| Eliquis | Apixaban | 36 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 21 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 34 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | 11 |
| Benazepril Hcl | Benazepril Hcl | 31 | 11 |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Celecoxib | Celecoxib | 31 | 14 |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Spironolactone | Spironolactone | 27 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 22 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 16 |
| Cilostazol | Cilostazol | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 19 |
| Azithromycin | Azithromycin | 18 | 15 |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Prednisone | Prednisone | 16 | 13 |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Lactulose | Lactulose | 12 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,507.71 · 76 records | ABBVIE INC. | AIRSUPRA, Auvelity, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, GEMTESA, Kerendia, Korlym, MOUNJARO, OTEZLA, Omnipod, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SUBLOCADE, TRELEGY ELLIPTA, UBRELVY, VERQUVO, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error